Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at HC Wainwright

Key Points

• HC Wainwright lowered Celcuity’s price target from $155 to $150 but maintained a Buy rating; the new target implies 124.58% upside from the prior close.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus and a $151.79 average price target, though one analyst rates it Hold and two rate it Sell.
• Celcuity reported a quarterly loss of $1.21 per share, beating the consensus estimate of a $1.51 loss by $0.30.

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective dropped by equities research analysts at HC Wainwright from $155.00 to $150.00 in a research report issued on Monday, Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 124.58% from the company's previous close.

A number of other research analysts have also commented on the company. TD Cowen reaffirmed a "buy" rating and issued a $145.00 price objective on shares of Celcuity in a report on Wednesday, October 21st. Citigroup reissued a "market outperform" rating on shares of Celcuity in a report on Monday. Royal Bank Of Canada cut shares of Celcuity to a "neutral" rating in a research report on Wednesday, October 28th. Needham & Company LLC decreased their price target on shares of Celcuity from $140.00 to $134.00 and set a "buy" rating on the stock in a research note on Wednesday, September 30th. Finally, Citizens Jmp reaffirmed a "market outperform" rating and set a $177.00 price target on shares of Celcuity in a research report on Monday, August 17th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $151.79.

Celcuity Price Performance

NASDAQ:CELC opened at $66.79 on Monday. The firm's fifty day moving average price is $75.11 and its two-hundred day moving average price is $99.38. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The company has a market cap of $3.27 billion, a P/E ratio of -14.18 and a beta of 0.16. Celcuity has a one year low of $53.54 and a one year high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, topping the consensus estimate of ($1.51) by $0.30. Equities analysts expect that Celcuity will post -4.98 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in shares of Celcuity during the fourth quarter valued at approximately $1,058,000. California State Teachers Retirement System raised its holdings in shares of Celcuity by 91.2% during the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company's stock valued at $2,920,000 after acquiring an additional 12,201 shares in the last quarter. Bank of America Corp DE purchased a new stake in Celcuity in the second quarter worth $153,928,000. E Fund Management Co. Ltd. purchased a new stake in Celcuity in the second quarter worth $4,802,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Celcuity in the second quarter valued at $2,927,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways.

Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

Founded in 2012 and headquartered in Minneapolis, Minnesota, Celcuity conducts clinical development in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.